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Objectives. The aim of this study was to assess the effectiveness of SPECT/CT for volume measurements and to report a
case illustrating the major impact of SPECT/CT in calculating the vascularized liver volume and dosimetry prior to injecting
radiolabelled yttrium-90 microspheres (Therasphere). Materials and Methods. This was a phantom study, involving volume
measurements carried out by two operators using SPECT and SPECT/CT images. The percentage of error for each method was
calculated, and interobserver reproducibility was evaluated. A treatment using Therasphere was planned in a patient with three
hepatic arteries, and the quantitative analysis of SPECT/CT for this patient is provided. Results. SPECT/CT volume measurements
proved to be accurate (mean error <6% for volumes ≥16 cm3) and reproductive (interobserver agreement = 0.9). In the case
report, 99mTc-MAA SPECT/CT identiﬁed a large liver volume, not previously identiﬁed with angiography, which was shown to be
vascularized after selective MAA injection into an arterial branch, resulting in a large modiﬁcation in the activity of Therasphere
used. Conclusions. MAA SPECT/CT is accurate for vascularized liver volume measurements, providing a valuable contribution to
the therapeutic planning of patients with complex hepatic vascularization.
1. Introduction
Hepatocellular carcinoma (HCC) is a common cancer, and
its treatment is difficult. A locoregional treatment may be
proposed to certain patients, involving either chemoembol-
ization or radioembolization. For radioembolization, 131I-
lipiodol has been used for many years with good results [1],
but its use is limited by major radioprotection problems.
Recently, radioembolization using microspheres labeled
with yttrium-90 has been developed, notably TheraSphere
(MDS Nordion, Ottawa, Canada) [2–6]. This approach is
based on delivering a high radioactive dose to the liver
volume to be treated.When both lobes are affected, two treat-
ments must be carried out at 1-month interval in order
to minimize the risk of radiation-induced side effects [4].
The treatment requires a ﬁrst diagnostic angiography, with
the aim of coiling collateral gastrointestinal vessels and per-
forming an MAA scintigraphy in order to obtain a perfusion
hepatic scintiscan and calculate the percentage of pulmonary
shunt.
The activity to be injected (Ainj) is calculated based on
a well-deﬁned model. The aim is to deliver a dose D(Gy)
of 120 ± 20Gy to the volume to be treated. This dose is
calculated according to the following formula that is based
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on the previously described MIRD formalism [5] and widely
used:
D(Gy) =
Ainj(GBq) · (1− S) · 50
M(Kg)
, (1)
where S represents the percentage of pulmonary shunt and
M the mass of vascularized hepatic volume, with the mass of
volume to be treated corresponding to the volumemultiplied
by a correction factor of 1.03 [5]. This volume corresponds
to the volume of the hepatic parenchyma vascularized by
the hepatic artery into which the microspheres are injected.
Generally, the calculation is based on CT.
A precise calculation of the vascularized volume is essen-
tial for dosimetric calculation, including the activity to be
administered.
The vascularized or functional liver volume may also be
analyzed using a vascular tracer such as human albumin
serum labeled with technetium-99m (99mTc-MAA): the vol-
ume of distribution of 99mTc-MAA following selective in-
jection into the hepatic artery, at the same position where
the microspheres are to be injected, reﬂects the vascularized
volume of the lobe to be treated.
In the absence of anatomical vascular variations, the def-
inition of the vascularized liver volume is relatively easy to
assess using CT. Contrarily, this calculation is much more
problematic in the event of anatomical variations, such as
when three distinct arterial branches vascularize the liver,
a situation encountered in about 10% to 30% of patients
[6]. It is assumed that the right vascular branch vascularizes
segments 6 and 8, the central branch segment 5 and 7, the
left branch segments 2, 3, and 4, while the inconsistent vascu-
larization of segment 1 is widely recognized. Given this case
scenario, MAA scintigraphy, which is mandatory for eval-
uating lung shunting, may be used for calculating the func-
tional liver volume vascularized by each arterial branch.
SPECT has already been employed for calculating func-
tional volumes [7, 8] although it may lead in certain cases to
volume overestimation due to the thresholdingmethod used.
In addition, PET has been reported to be useful for functional
volume measurements, in particular in deﬁning the volumes
of irradiation [9–11]. Themethod used for volume deﬁnition
(simple visual method or based on an isocontour with pre-
deﬁned threshold) was shown to signiﬁcantly impact on the
achieved values [10].
While the use of SPECT/CT has not yet been reported
in this setting, SPECT/CT-fused images may be helpful in
delineating volumes, which may prove to be a reliable meas-
urement of functional volumes. SPECT/CT may also be used
to measure the tumor volume and nontumoral injected liver
volume in order to calculate the doses absorbed by the tumor
and the nontumoral liver, respectively.
In this paper, we report on a phantom study aimed at val-
idating volume measurements based on SPECT/CT. We also
stress the advantages of SPECT/CT in computing the vas-
cularized liver volume in addition to calculating the doses
absorbed by the healthy liver and tumor in a patient with
complex hepatic vascularization.
2. Materials andMethods
2.1. Phantom Study. We carried out a study on phantoms in
order to validate the volume measurements performed using
SPECT/CT. Various phantoms were used, including a cylin-
drical Jaszack phantom with a volume of 6,716mL (cylinder
1) and two cylindrical phantoms of 774 (cylinder 2) and
473mL (cylinder 3) for the measurement of large volumes
(mimicking the liver). Spheres 1, 2, 3, and 4 of 55, 20.5,
16, and 8mL, respectively, were used and inserted into the
Jaszack phantom for measuring small representative tumor
volumes. The activities of 99mTc used for phantoms repre-
sentative of the liver (cylinder 1, 2, and 3) ranged from 55
to 170MBq. For the spheres, activities of 18.5, 37, 55.5, and
74MBq were used. These activities were chosen in order to
simulate standard clinical situations involving an injection of
185 MBq of 99mTc-MAA in a liver of 1500mL, with tumor
uptake of 10%, 20%, 30%, and 40% of the injected activities,
respectively.
SPECT/CT acquisitions were performed (32 projections,
180◦, 128∗128, 30 s/projection, Symbia T2 gantry, Siemens).
SPECT imaging data was reconstructed using an iterative
method (OSEM) with attenuation and scatter correction,
and images were then visualized with or without fusion with
CT scan data.
Volume measurement was carried out on SPECT and
SPECT/CT images using a Syngo data-processing console
display unit (Siemens) with “Volume Analysis” software.
This software allowed us to generate semi-automatically the
volume-of-interest (VOI) in the liver and tumor by means of
an isocontour deﬁnition method. Each voxel with an activity
reaching or exceeding a threshold percentage of the highest
activity was included in the VOI.
For each volume measurement, the isocontour was ﬁtted
by superposition on either the contour of the hot spot located
by SPECT alone or the internal wall of the phantom located
on the SPECT/CT fusion images (Figure 1).
Measurements of volumes by SPECT and SPECT/CT
were carried out by two operators blinded to the phantom
volumes.
2.2. Statistical Analysis. For each method, the percentage of
error was calculated by reference to the actual volume of the
phantoms. The interobserver reproducibility was evaluated
using the Bland-Altman test of agreement, with values ≥0.8
considered to be excellent, values in the range of 0.6–0.8 to
be good, values in the range of 0.4–0.6 to be poor, and values
<0.4 to be very poor.
2.3. Case Report and Dosimetric Aproach. We report on the
case of a 63-year-old patient with a voluminous HCC inﬁl-
trating the whole left liver (Figure 2) along with portal vein
thrombosis, who was addressed to our center for radioem-
bolization with 90Y-loaded glass microspheres.
At the end of the diagnostic angiography, 185MBq of
99mTc-MAA was injected selectively for SPECT/CT. The pa-
rameters of acquisition and reconstruction were the same as
those used for the phantom study. SPECT/CT quantitative
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Figure 1: Delineation of VOIs used for quantitative analysis of SPECT and SPECT/CT analysis (a, b): VOI deﬁned on SPECT hot spot alone.
Fused SPECT/CT image with the VOI matching with the hot spot ((a), SPECT/CT scale); CT scale showing that the VOI is not accurate
and larger than the sphere (b). (c): VOI deﬁned with SPECT/CT and using the CT scale: the isocontour was ﬁtted by superposition on the
boundaries of the internal wall of the sphere.
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Figure 2: case report: patient with a large HCC Contrast enhanced CT evidencing a large inﬁltrative tumor of the left liver (a) with a portal
vein thrombosis (b).
analysis (volume and count measurements) was conducted
on the fusion images. For each VOI, the threshold value was
adjusted so that the isocontours of the distribution volume
of MAA were superimposed on the fusion images that cor-
responded to the contours of the liver and tumor (Figure
3). These VOIs were then used to measure the distribution
volume of 99mTc-MAA in the liver and tumor (expressed in
mL) in addition to the total activity (expressed in counts)
contained in the liver (CPL) and tumor (CPtum). Volume and
total counts in the healthy liver (CPHL) were calculated by
subtracting liver and tumor parameters.
The dose absorbed by the tumor was calculated based on
the standard formula as follows:
Dtum(Gy) =
Atum(GBq) · 50
Wtum(Kg)
, (2)
where Atum = activity contained in the tumor expressed in
GBq, Atum = (Ainj(GBq) · (1 − S) · CPtum)/((CPtum + CPHL)),
Wtum =mass of tumor.
The dose absorbed by the healthy injected liver was cal-
culated based on the standard formula as follows:
DHL(Gy) =
AHL(GBq) · 50
WHL(kg)
, (3)
where AHL = activity contained in the healthy liver expressed
in GBq, AHL = (Ainj(GBq) · (1− S) ·CPHL)/((CPHL +CPtum)),
WHL =mass of healthy liver.
The Therasphere injection was administered 8 days later
during the second angiography, with the aim to administer a
dose of 120 ± 20Gy to the vascularized volume.
3. Results
3.1. Phantom Study. In total, acquisitions andmeasurements
were carried out on 23 test objects of different conﬁguration
(size and activity), with results for both operators provided
in Tables 1 and 2.
For SPECT alone, mean errors of volume measurements
were relatively high (>20%, Table 3), which was due to
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Figure 3: Case report: delineation of the tumoral and injected lover VOI on SPECT/CT whole; injected liver VOI with SPECT/CT color
scale (a), whole injected liver VOI with CT scale and visualisation of SPECT isocontour (b), tumoral VOI with SPECT/CT color scale (c)
and tumoral VOI with CT scale and visualisation of SPECT isocontour (d).
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Figure 4: Case report: angiographic and scintigraphic data; right selective angiography (a), selective angiography of the common hepatic
artery vascularizing segment IV and the left liver (b), SPECT (c) and SPECT/CT (d) after injection of the MAA at the level of the central
hepatic artery revealing an unexpected uptake in the right liver, in addition to the expected uptake of segment IV and left liver (whole liver
distribution, volume 1829cc).
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Table 1: Operator 1 results.
Phantom conﬁguration
True sphere/
background ratio
SPECT alone SPECT- CT
Isocontour
(%)
Measured
volume
(cm3)
Error
(%)
Isocontour
(%)
Measured
volume
(cm3)
Error Vol.
(%)
18,5MBq/sphere
Cylinder 1 — 2% 6521 −2,90 2% 6521 −2,90
Sphere 1 2.8 42% 75,45 37,18 48% 57,22 4,04
Sphere 2 7.6 31% 22,35 6,43 27% 27,08 28,95
Sphere 3 9.6 27% 18 12,50 29% 16,94 5,88
Sphere 4 19.6 15% 14,72 84,00 19% 10,91 36,38
37MBq/sphere
Cylinder 1 — 2% 6180 −7,98 1% 6735 0,28
Sphere 1 6 46% 44,86 −18,44 42% 49,06 −10,80
Sphere 2 17 25% 22,58 7,52 29% 20,52 −2,29
Sphere 3 23.4 23% 17,55 9,69 27% 14,95 −6,56
Sphere 4 43.8 31% 10,45 30,63 35% 9,08 13,50
55,5MBq/sphere
Cylinder 1 — 1% 6737 0,31 1% 6737 0,31
Sphere 1 9.9 44% 45,32 −17,60 31% 59,28 7,78
Sphere 2 29.6 33% 18,62 −11,33 31% 19,3 −8,10
Sphere 3 38.6 33% 17,32 8,25 35% 16,17 1,06
Sphere 4 73.1 31% 14,37 79,63 40% 10,53 31,63
74MBq/sphere
Cylinder 1 — NA NA NA NA NA NA
Sphere 1 16 52% 33,72 −38,69 31% 54,86 −0,25
Sphere 2 45 21% 23,5 11,90 27% 19,81 −5,67
Sphere 3 57 21% 18,05 12,81 27% 15,49 −3,19
Sphere 4 114 31% 5,95 −25,63 21% 8,32 4,00
55MBq Cylinder 2 — 46% 709 −8,40 25% 795 2,71
116MBq Cylinder 2 — 46% 667 −13,82 35% 770 −0,52
72MBq Cylinder 3 — 33% 455 −3,81 23% 515 8,88
2010
Figure 5: Case report: follow-up CT scan 4 months after injection
of 5GBq of in the central branch: major response.
over- or underestimation of volumes by observer 1 and, more
frequently, to large volume overestimation by observer 2.
Interobserver reproducibility was inadequate with
SPECT alone, as the Bland-Altman test result was only 0.2.
For SPECT/CT, results were superior, as mean errors of
measurement were <10% for the two operators, being <6%
for the measurement of volumes ≥16 cm3 and even <2.5%
for volumes ≥473mL (Table 3). Interobserver reproducibil-
ity was good when using SPECT/CT, with a Bland-Altman
test result of 0.9.
3.2. Case Report and Dosimetric Approach. Diagnostic angi-
ography revealed an anatomical variant with three arterial
branches vascularizing the liver: a right hepatic artery orig-
inating from the mesenteric artery (Figure 4(a)), and a com-
mon hepatic artery from the celiac trunk leading to a central
branch and left branch vascularizing the central and left liver,
respectively (probably segments 2, 3, and 4 but not the whole
liver; see Figure 4(b)).
Unexpectedly, after injecting MAA into the common he-
patic branch, SPECT/CT revealed the whole liver distribu-
tion of the MAA (Figure 4(c)).
After injecting contrast or MAA into the common hep-
atic branch, the vascularized liver volume was only 346mL
based on angiographic + CT data versus 1829mL with quan-
titative MAA SPECT. Moreover, the tumoral uptake calcu-
lated using quantitativeMAA SPECT data represented 69.1%
of the total liver uptake with no lung shunting apparent.
Based on angiographic + CT, the activity of 90Y-loaded
microspheres to be injected in order to obtain a dose of
120Gy in the injected volume, presumed to be only the left
liver, would have been 0.8GBq.
Based on quantitative MAA SPECT analysis, a 5GBq
activity was planned to be used, resulting in a dose of 132Gy
to the vascularized liver (whole liver), a tumoral dose of
275Gy, and a nontumoral injected liver dose of only 57Gy.
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Table 2: Opertor 2 results.
Phantom conﬁguration
True sphere/
background ratio
SPECT alone SPECT-CT
Isocontour
(%)
Measured
volume
(cm3)
Error
(%)
Isocontour
(%)
Measured
volume
(cm3)
Error (%)
18,5MBq/sphere
Cylinder 1 — 1% 7087 5,52 2% 6521 −2,90
Sphere 1 2.8 31% 207 276,36 48% 57,2 4,00
Sphere 2 7.6 13% 104,5 397,62 28% 24,4 16,19
Sphere 3 9.6 19% 27,4 71,25 29% 16,9 5,62
Sphere 4 19.6 8% 29,2 265,00 19% 10,9 36,25
37MBq/sphere
Cylinder 1 — 2% 6180 −7,98 1% 6700 −0,24
Sphere 1 6 7% 169,7 208,55 34% 53,56 −2,62
Sphere 2 17 3% 113,7 441,43 23% 24,34 15,90
Sphere 3 23.4 3% 119,78 648,63 27% 14,9 −6,88
Sphere 4 43.8 4% 53,48 568,50 33% 9,8 22,50
55,5MBq/sphere
Cylinder 1 — 1% 6737 0,31 1% 6737 0,31
Sphere 1 9.9 10% 159,3 189,64 35% 55,7 1,27
Sphere 2 29.6 4% 85 304,76 25% 22,7 8,10
Sphere 3 38.6 7% 51,5 221,88 36% 15,5 −3,13
Sphere 4 73.1 6% 44,1 451,25 36% 12 50,00
74MBq/sphere
Cylinder 1 — 1% 6565 −2,10 1 6565 −2,10
Sphere 1 16 15% 99,5 80,91 32% 56 1,82
Sphere 2 45 6% 54,1 157,62 23% 23,7 12,86
Sphere 3 57 5% 42,8 167,50 25% 17,4 8,75
Sphere 4 114 2% 35,8 347,50 20% 8,7 8,75
55MBq Cylinder 2 — 17% 887 14,60 27% 801 3,49
116MBq Cylinder 2 — 19% 855 10,47 29% 775 0,13
72MBq Cylinder 3 — 21% 520 9,94 27% 481 1,69
Table 3: Mean error (±1 standard deviation) with SPECT and SPECT/CT volume measurements.
SPECT alone SPECT/CT
All volumes volumes ≥16mL volumes ≥473mL All volumes volumes ≥16mL volumes ≥473mL
Operator 1 20.4 ± 22.4% 12.8 ± 10.3% 6.2 ± 4.8% 8.5 ± 10.5% 5.6 ± 6.7% 2.2 ± 3.1%
Operator 2 210.8 ± 194.5% 169.3 ± 181.3% 7.2 ± 4.9% 9.4 ± 12.3% 5.2 ± 5.1% 1.5 ± 1.3%
Based on quantitative MAA SPECT/CT analysis instead
of standard angiographic and CT data, the patient was treat-
ed with 5GBq Therasphere. No toxicity was observed, and a
major response was achieved (Figure 5). At the last follow-up
visit, 14 months after treatment, the patient showed no ev-
idence of recurrence.
4. Discussion
SPECT is currently used to deﬁne functional volumes of
different organs such as the liver [7, 8], and the difficulties
relating to the thresholding methods are widely recognized.
This is particularly true in the case of small volumes and
organs with low contrast (organ/background ratio <5) [12].
Data pertaining to SPECT for the calculation of tumoral
volume is scare. Tumoral volume measurements have been
extensively reported and are still being performed using PET
for deﬁning the volumes of irradiation [9–11]. However, due
to the variability in the thresholding methods resulting in
widely variable data, determining tumoral volumes based on
PET images is still challenging [9]. For example, using dif-
ferent approaches for volume deﬁnition (visual evaluation,
isocontour with a 40% threshold, isocontour with a 2.5 SUV
threshold, and adaptive tumor/background ratio thresh-
old) Lee [10] showed that volumes generated were highly
dependent on the method used with intermethod variability
exceeding 100%.
We describe a new method of organ and tumor volume
calculation based on SPECT/CT data using simple manufac-
tured software. This adaptive thresholdingmethod was based
on a direct visualization of tumoral and liver boundaries on
SPECT/CT images, avoiding the use of thresholds dependent
on predeﬁned values. We showed that SPECT alone (visual
delimitation of the volume based on the hot spot) was
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acceptable for large volumes (error <10% for volumes
>473mL), but inaccurate for small volumemeasurements, in
line with previously published literature. In fact, visual vol-
ume deﬁnition is highly dependent on the individual investi-
gator and display window setting (type of grey or color win-
dow and saturation used), potentially leading to large vol-
ume over- or underestimation [10]. With the SPECT/CT
quantitative method used in our study, the anatomical
information supplied by CT allows for VOI guidance so that
the deﬁnition of volumes is not only based on the visual ad-
justment of VOI on uptake, but also on the anatomical out-
lines of both liver and tumor. This approach turned out to
be highly accurate, as the error of measurement was <6% for
volumes larger than 16mL and even <2.5% for very large vol-
umes, such as the liver, with excellent interobserver agree-
ment.
The case reported in our study clearly demonstrates that
in patients with anatomical abnormalities in liver vascular-
ization, MAA SPECT/CT vascularized volume measurement
is a more functional and reliable method than volume cal-
culations using the anatomical Couinaud segmentation
based on angiographic and CT data. In our case report, due
to MAA SPECT/CT, we were able to detect an unexpectedly
large volume of liver slightly vascularized after selective injec-
tion of MAA into the common hepatic branch. This meth-
od revealed the existence of microvascular communications
between different anatomic segments, probably via intra-
tumoral arterioportal shunts with low arterial blood ﬂow,
which were not visible on angiography but detected using
MAA SPECT/CT.
The therapeutic impact for our patient was crucial, since
it led us to signiﬁcantly increase the activity injected for treat-
ment, 5 GBq instead of 0.8 GBq, without any toxicity but an
excellent response.
Furthermore, the evaluation of tumor and healthy liver
doses based on the quantitative analysis of SPECT/CT is of
great interest. In fact, the dose absorbed by the tumor rep-
resents the parameter most likely to correlate with response.
This parameter depends directly on the quantity of radioac-
tivity ﬁxed in the tumor (i.e., degree of vascularization) as
well as the total quantity of microspheres injected. Only
MAA SPECT/CT allows us to evaluate this parameter, which
corresponds to the tumoral absorbed dose.
5. Conclusion
The effectiveness and reproducibility of MAA SPECT/CT
volume measurements was conﬁrmed by a phantom study,
with a mean error <6% for volumes ≥16mL and <2.5% for
larger volumes, such as the whole liver. MAA SPECT/CT
appears to be a more functional tool in identifying and
calculating vascularized liver volumes than angiography, as
it is able to identify unexpected vascularized areas with low
blood ﬂow not recognizable by angiography. In addition,
quantitative MAA SPECT/CT allows for calculating the
tumoral absorbed and nontumoral injected liver doses.
Therefore, quantitative MAA SPECT/CT may be of great
help in deﬁning vascularized liver volumes and calculating
the activity to be administered, especially in patients with
complex hepatic vascularization. Quantitative MAA SPECT/
CT may be instrumental in optimizing the activity to be
injected, thereby increasing the therapeutic effectiveness.
Nonetheless, this hypothesis must still be validated in con-
trolled studies.
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